海角视频

Oops.

Our website is temporarily unavailable in your location.

We are working hard to get it back online.

PRIVACY
Enterprise

Astrazeneca bows to Donald Trump and slashes US drug prices by up to 80%

The Cambridge-based pharma giant said it will provide direct-to-consumer sales to eligible patients with prescriptions for chronic diseases at a discount of up to 80 per cent off list prices

Corporate logos are seen outside the Macclesfield factory of AstraZeneca (Image: Getty Images)

AstraZeneca has succumbed to pressure from US president Donald Trump to reduce the cost of its medications for American patients.

The Cambridge-headquartered pharmaceutical giant announced it will offer direct-to-consumer sales to qualifying patients with prescriptions for chronic conditions at discounts of up to 80 per cent off list prices, whilst also joining the US government's new direct purchasing platform, enabling patients to buy medicines at reduced cash prices, as reported by .

AstraZeneca stated the initiative, which satisfies the rigorous new demands Trump has placed on pharmaceutical companies, would enable it to avoid any tariffs levied on the sector for at least the next three years.

However, the company did not outline the scale of the financial impact it would face from the price reductions.

Pascal Soriot, Chief Executive Officer, AstraZeneca, said the move "helps safeguard America's pioneering role as a global powerhouse in innovation and developing the next generation of medicines."

"It is now essential other wealthy countries step up their contribution to fund innovation."

AstraZeneca's pivot to the US

The initiative represents the latest indication of AstraZeneca's shift towards the US to avoid Donald Trump's ire as he threatens tariffs on pharmaceutical companies, citing pricing disparities between medicines sold in the US and elsewhere. In July, the company revealed intentions to invest up to $50bn in US manufacturing and R&D after abandoning its 海角视频 expansion plans, dealing a setback to the government's industrial strategy.

The business stated it would deploy this substantial sum over the coming five years, including on a new Virginia manufacturing facility representing its largest-ever single manufacturing investment.